SCHEMBL29964580

SCHEMBL29964580

CCN1CCOCC1c1ccc(-c2cc(-c3ccc4c(c3)CCNC4=O)c(N)nc2F)cc1

nearest known ligand 0.46

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPK1 P28482 1/20 0.46
PARP10 Q53GL7 5/20 0.37
PARP11 Q9NR21 5/20 0.37
MAPKAPK2 P49137 7/20 0.36
MTOR P42345 2/20 0.35
MAPK9 P45984 1/20 0.35
CDK4 P11802 1/20 0.35
CCND1 P24385 1/20 0.35
CCND3 P30281 1/20 0.35
CDK6 Q00534 1/20 0.35
DRD2 P14416 1/20 0.35
DRD3 P35462 1/20 0.35
GSK3B P49841 1/20 0.34
EED O75530 1/20 0.34
RBBP4 Q09028 1/20 0.34
SUZ12 Q15022 1/20 0.34
EZH2 Q15910 1/20 0.34
AEBP2 Q6ZN18 1/20 0.34
GABRG2 P18507 1/20 0.33
GABRB3 P28472 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL31078978 0.91 MAPK1 (0.46) MAPK1PARP10PARP11MAPKAPK2MTOR
SCHEMBL29964054 0.90 MAPK1 (0.43) MAPK1PARP10PARP11MAPKAPK2MTOR
SCHEMBL31079306 0.89 MAPK1 (0.43) MAPK1PARP10PARP11MAPKAPK2MAPK9
SCHEMBL31079199 0.87 MAPK1 (0.46) MAPK1PARP10PARP11MAPKAPK2MTOR
SCHEMBL29964832 0.87 MAPK1 (0.47) MAPK1PARP10PARP11MAPKAPK2MTOR
SCHEMBL24681082 0.85 MAPK1 (0.56) MAPK1PARP10PARP11MAPKAPK2MAPK9
SCHEMBL29914558 0.85 MAPK1 (0.56) MAPK1PARP10PARP11MAPKAPK2MAPK9
SCHEMBL29963949 0.81 MAPK1 (0.52) MAPK1PARP10PARP11MAPKAPK2MAPK9
SCHEMBL29964622 0.81 MAPK1 (0.49) MAPK1PARP10PARP11MAPKAPK2MAPK9
SCHEMBL29964192 0.81 MAPK1 (0.44) MAPK1PARP10PARP11MAPKAPK2MAPK9

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20240343704-A1 HALO-SUBSTITUTED AMINO PYRIDINE COMPOUNDS AS INHIBITORS OF THE HAEMATOPOIETIC PROGENITOR KINASE 1 (HPK1) ONTARIO INSTITUTE FOR CANCER RESEARCH (OICR) (CA) 2024-10-17 US disclosed
WO-2022226668-A1 HALO-SUBSTITUTED AMINO PYRIDINE COMPOUNDS AS INHIBITORS OF THE HAEMATOPOIETIC PROGENITOR KINASE 1 (HPK1) ONTARIO INSTITUTE FOR CANCER RESEARCH (OICR) (CA) 2022-11-03 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20240343704-A1 HALO-SUBSTITUTED AMINO PYRIDINE COMPOUNDS AS INHIBITORS OF THE HAEMATOPOIETIC PROGENITOR KINASE 1 (HPK1) CMPK1, WNK1, AAK1 MAPK1 141/4885PARP10 2072/4885PARP11 1176/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.